Changes of cytokines and thyroid function in patients with recurrent breast cancer

Anticancer Research

Volumn 17, Issue 1 B, 1997, Pages 695-699

  Yokoe, Takao ^a   Iino, Yuichi ^a   Takei, Hiroyuki ^a   Horiguchi, Jun ^a   Koibuchi, Yukio ^a   Maemura, Michio ^a   Ohwada, Susumu ^a   Morishita, Yasuo ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Cytokine; IL 6; IL 8; Recurrent breast cancer; Thyroid hormone

Indexed keywords

CYTOKINE; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; LIOTHYRONINE; THYROTROPIN; THYROXINE;

ADULT; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; HOST RESISTANCE; HUMAN; HYPOTHYROIDISM; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; THYROID FUNCTION;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; INTERLEUKIN-2; INTERLEUKIN-6; INTERLEUKIN-8; MIDDLE AGED; NEOPLASM PROTEINS; THYROXINE; TRIIODOTHYRONINE;

EID: 0031043774     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Kushner I: The acute phase response: An overview. Methods Enzymol 163: 373-383, 1988.
2. Strassman G, Fong M, Kenney JS and Jacob CO: Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest 89: 1681-1684, 1992.
3. Pittman CS, Suda AK, Chambers JB Jr, McDaniel HG, Ray GY and Preston BK: Abnormalities of thyroid hormone turnover in patients with diabetes mellitus before and after insulin therapy. J Clin Endocrinol Metab 48: 854-860, 1979.
4. Wiersinga WM, Lie KI and Touber JL: Thyroid hormones in acute myocardial infarction. Clin Endocrinol 14: 367-374, 1981.
5. Lim VS, Fang VS, Kats AI and Refetoff S: Thyroid dysfunction in chronic renal failure. J Clin Invest 60: 522-534, 1977.
6. Nomura S, Pittman CS, Chambers JB Jr, Buck MW and Shimizu T: Reduced peripheral conversion of thyroxine to triiodothyronine in patients with hepatic cirrhosis. J Clin Invest 56: 643-652, 1975.
7. Kaptein EM, Spencer CA, Kamiel MB and Nicoloff JT: Prolonged dopamine administration and thyroid hormone economy in normal and critically ill subjects. J Clinic Endocrinol Metab 51: 387-393, 1980.
8. Van den Berghe G, de Zegher F and Lauwers P: Dopamine suppresses pituitary function in infants and children. Crit Care Med 22: 1747-1753, 1994.
9. Van den Berghe G, de Zegher F and Lauwers P: Dopamine and the sick euthyroid syndrome in critical illness. Clin Endocrinol 41: 713-737, 1994.
10. Mechlis S, Lubin E, Laor J, Margaliot M and Strasberg B: Amiodarone-induced thyroid gland dysfunction. Am J Cardiol 59: 833-835, 1987.
11. Albert SG, Alves LE and Rose EP: .Thyroid dysfunction during chronic amiodarone therapy. J Am Coll Cardiol 9: 175-183, 1987.
12. Trip MD, Wiersinga W and Plomp TA: Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism. Am J Med 91: 507-511, 1991.
13. Yokoe T, Iino Y, Takei H, Horiguchi J, Koibuchi Y, Maemura M, Ohwada S and Morishita Y: Relationship between thyroid-pituitary function and response to therapy in patients with recurrent breast cancer. Anticancer Res 1996 (in press).
14. Chopra IJ, Teco GNC, Nguyen AH and Solomon DH: In search of an inhibitor of thyroid hormone binding to serum proteins in nonthyroidal illnesses. J Clin Endocrinol Metab 49: 63-69, 1979.
15. Mooradian AD, Reed RL, Osterweil D, Schiffman R and Scureri P: Decreased serum triiodothyronine is associated with increased concentration of tumor necrosis factor. J Clin Endocrinol Metab 71: 1239-1242, 1990.
16. Boelen MC, Schiphorst P-T and Wiersinga: Association between serum interleukin-6 and serum 3,5,3′-triiodothyronine in nonthyroidal illness. J Clin Endocrinol Metab 77: 1695-1699, 1993.
17. Bartalena L, Brogioni S, Grasso L, Veiluzzi F and Martino E: Relationship of the increased serum interleukin-6 concentration to change of thyroid function in nonthyroidal illness. J Endocrinol Invest 27: 269-274, 1994.
18. Stouthard JML, Van der Poll, Endert E, Bakker PJM, Veenhof CHN, Sauerwein HP and Romijn JA: Effects of acute and chronic interleukin-6 administration on thyroid hormone metabolism in humans. J Clin Endocrinol Metab 79: 1324-1346, 1994.
19. Schwartzentruber DJ, White DE, Zweig MH, Weintraub BD and Rosenberg SA: Thyroid dysfunction associated with immunotherapy for patients with cancer. Cancer 68: 2384-2390, 1991.
20. Atkins MB, Mier JW, Parkinson DR, Groud JA, Beckman EM and Kaplan MM: Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. New Engl J Med 318: 1557-1563, 1988.
21. World Health Organization: Handbook for reporting results of cancer treatment. Geneva, World Health Organization, 1979.
22. Takaku F: Clinical application of cytokines for cancer treatment. Oncology 51: 123-128, 1994.
23. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG and White DE: A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high interleukin-2 alone. N Engl J Med 316: 889-905, 3987.
24. Kowal-Vern A, Malenga JK, Hoppensteadt D, Sharp-Pucci M and Gamelli RL: Interleukin-2 and interleukin-6 in relation to burn wound size in the acute phase of thermal injury. J Am Coll Surg 178: 357-362, 1994.
25. Hirano T, Yasukawa K, Harada H, Taga T, Watanabe Y, Matsuda T, Kashiwamura S, Nakajima K, Koyama K, Iwamatsu A, Tsunasawa S, Sakiyama F, Matsui H, Takahara Y, Taniguchi T and Kishimoto T: Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324: 73-76, 1986.
26. Kishimoto T: The biology of interleukin-6. Blood 74: 1-10, 1989.
27. Speirs V, Adams EF, Rafferty B and White MC: Interactive effects of interleukin-6, 17 beta-estradiol and progesterone On growth and 17-beta-hydroxysteroid dehydrogenase activity in human breast carcinoma cells. J Steroid Biochem Molecul Biol 46: 11-15, 1993.
28. Danforth DN Jr and Sgagias MK: Interleukin-1 alpha and interleukin-6 act additively to inhibit growth of MCF-7 breast cancer cells in vitro. Cancer Res 53: 1538-1545, 1993.
29. Blais Y, Sugimoto K, Carriere MC, Haagensen DE, Labrie F and Simard J: Interleukin-6 inhibits the potent stimulatory action of androgens, glucocorticoids and interleukin-1 alpha on apolipoprotein D and GCDFP-15 expression in human breast cancer cells. Int J Cancer 62: 732-737, 1995
30. van Gameren MM, Willemse PH. Mulder NH. Limburg PC Groen HJ, Vellenga E and Vries EG: Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. Blood 84: 1434-1441, 1994.
31. Veldhuis GJ, Willemse PH, Sleijfer DT, van der Graaf WT, Groen HJ, Limburg PC, Mulder NH and de Vries EG: Toxicity and efficacy of escalating dosages of recombinant human interleukin-6 after chemotherapy in patients with breast cancer or non-small-cell lung cancer. J Clin Oncol 13: 2585-2593, 1995.
32. Reiter Z, Chen L Revel M and Rubinstein M: Interleukin-6 protects ductal breast carcinima cells from MHC-unrestricted cell-mediated cytotoxicity. Lymphokine Cytokine Res 11: 175-181, 1992.
33. Matsuda Y, Kawata S, Nagase T, Maeda Y, Yamasaki E, Kiso S, Ishiguro H and Matsuzawa Y: Interleukin-6 in transcatheter arterial embolization for patients with hepatocellular carcinoma. Effects of serine protease inhibitor. Cancer 73: 53-57, 1994.
34. Blay JY, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, Mercatello A, Ravault A, Tourani J-M, Moskovtchenko J-F, Philip T and Favrot M: Serum level of interleukin-6 as a prognostic factor in metastatic renal cell carcinoma. Cancer Res 52: 3317-3322, 1992.
35. Reed MJ, Topping L, Goldham NG, Purohit A, Ghilchik MW and James VHT: Control of aromatase activity in breast cancer cells: The roll of cytokines and growth factors. J Steroid Biochem Molec Biol 44: 589-596, 1993.
36. Purohit A. Ghilchik MW, Duncan L, Wang DY, Singh A, Walker MM and Reed MJ: Aromatase activity and interleukin-6 production by normal and malignant tissues. J Clin Endocrinol Metab 80: 3052-3058, 1995.
37. Detmers PA, Lo SK, Olsen-Egbert E, Walz A, Baggiolini M and Conn ZA: Neutrophil-activated protein 1/interluekin-8 stimulates the binding activity of the leukocyte adhesion receptor CD11b/CD18 on human neutrphils. J Exp Med 171: 1155-1162, 1990.
38. Huber AR< Kunkel SL, Todd RF III and Weiss SJ: Regulation of transendothelial neutrophil migration by endogeneous interleukin-8. Science 254: 99-102, 1991.
39. Basolo F, Conaldi PG, Fiore L, Calvo S and Toniolo A: Normal breast epithelial cells produce interleukin 6 and 8 together with tumor-necrosis factor: Defective IL6 expression in mammary carcinoma. Int J Cancer 55: 926-930, 1993.
40. Kaptein EM, Grieb DA, Spencer CA, Wheeler WS and Nicoloff JT: Thyroxine metabolism in the low thyroxine state of critical nonthyroidal illness. J Clin Endocrinol Metab 53: 764-771, 1981.
41. Brent GA and Hershman JM: Thyroxine therapy in patients with severe nonthyroidal illness and low serum thyroxine concentration. J Clin Endoclinol Metab 63: 1-8, 1986.
42. Davidson SB, Dulchavsky SA, Diebel LN, Dutta S and Cullen WJ: Effect of sepsis and 3,5,3′-triiodothyronine replacement on myocardial integrity during oxidant challenge. Crit Care Med 24: 850-854, 1996.
43. Walker JD, Crawford FA Jr, Mukherjee R, Zile MR and Spinale FG: Direct effects of acute administration of 3,5,3′-triiodo-L-thyronine on myocyte function. Ann Thorac Surg 58: 851-856, 1994.
44. Morkin E, Pennock GD, Raya TE, Bahl JJ and Goldman S: Studies on the use of thyroid hormone and a thyroid hormone analogue in the treatment of congestive heart failure. Ann Thorac Surg 56: S54-60, 1993.
45. Dulchavsky SA, Kenzenko SM, Saba AA and Diebel LN: Triiodothyronine (T3) supplementation maintains surfactant biochemical integrity during sepsis. J Trauma 39: 53-58, 1995.